RT Journal Article
SR Electronic
T1 Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 250
OP 252
DO 10.1212/01.wnl.0000194318.74946.b6
VO 66
IS 2
A1 Hersch, S. M.
A1 Gevorkian, S.
A1 Marder, K.
A1 Moskowitz, C.
A1 Feigin, A.
A1 Cox, M.
A1 Como, P.
A1 Zimmerman, C.
A1 Lin, M.
A1 Zhang, L.
A1 Ulug, A. M.
A1 Beal, M. F.
A1 Matson, W.
A1 Bogdanov, M.
A1 Ebbel, E.
A1 Zaleta, A.
A1 Kaneko, Y.
A1 Jenkins, B.
A1 Hevelone, N.
A1 Zhang, H.
A1 Yu, H.
A1 Schoenfeld, D.
A1 Ferrante, R.
A1 Rosas, H. D.
YR 2006
UL http://n.neurology.org/content/66/2/250.abstract
AB In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2′-deoxyguanosine (8OH2′dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.